SOLENO THERAPEUT. DL-001 Cash Flow Conversion Efficiency
SOLENO THERAPEUT. DL-001 cash flow conversion efficiency. Based on the latest financial reports, SOLENO THERAPEUT. DL-001 (6XC) has a cash flow conversion efficiency ratio of 0.108x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€48.70 Million ≈ $56.94 Million USD) by net assets (€450.12 Million ≈ $526.23 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of SOLENO THERAPEUT. DL-001 (2021–2025)
Cash flow conversion efficiency of SOLENO THERAPEUT. DL-001 from 2021 to 2025. This chart illustrates how SOLENO THERAPEUT. DL-001's cash flow conversion efficiency has evolved over time, based on yearly financial data. View 6XC share price today for real-time trading data and today's change.
SOLENO THERAPEUT. DL-001 Cash Flow Conversion Ratio Explained
SOLENO THERAPEUT. DL-001 cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
SOLENO THERAPEUT. DL-001 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of SOLENO THERAPEUT. DL-001 ranked by their cash flow conversion efficiency. Also see 6XC company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hangzhou Cable
SHG:603618
|
-0.063x |
|
TAV HAVALIMAN.HLDG ADR/4
F:5THA
|
-0.065x |
|
Enerflex Ltd.
TO:EFX
|
0.046x |
|
Ternium Argentina SA
BA:TXAR
|
0.014x |
|
Allos S.A.
SA:ALOS3
|
0.034x |
|
Regional S.A.B. de C.V
MX:RA
|
-0.054x |
|
KEPCO Engineering & Construction
KO:052690
|
-0.010x |
|
Calix Inc
NYSE:CALX
|
0.020x |
Annual Cash Flow Conversion Efficiency for SOLENO THERAPEUT. DL-001 (2021–2025)
The table below shows the annual cash flow conversion efficiency of SOLENO THERAPEUT. DL-001 from 2021 to 2025. Review how much free cash does SOLENO THERAPEUT. DL-001 generate to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €450.12 Million ≈ $526.23 Million |
€46.80 Million ≈ $54.71 Million |
0.104x | +136.88% |
| 2024-12-31 | €245.11 Million ≈ $286.56 Million |
€-69.10 Million ≈ $-80.78 Million |
-0.282x | -78.03% |
| 2023-12-31 | €157.51 Million ≈ $184.14 Million |
€-24.94 Million ≈ $-29.16 Million |
-0.158x | +92.12% |
| 2022-12-31 | €10.35 Million ≈ $12.10 Million |
€-20.78 Million ≈ $-24.30 Million |
-2.008x | -28.67% |
| 2021-12-31 | €17.79 Million ≈ $20.80 Million |
€-27.77 Million ≈ $-32.47 Million |
-1.561x | -- |
About SOLENO THERAPEUT. DL-001
Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is VYKAT XR, an extended-release tablets for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeut… Read more